International Journal of
Reproductive Biomedicine
Thu, Apr 25, 2024
[Archive]
Volume 11, Issue 8 (11-2013)
IJRM 2013, 11(8): 611-0 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Amooee S, Parsanezhad M E, Ravanbod Shirazi M, Alborzi S, Samsami A. Metformin versus chromium picolinate in clomiphene citrate-resistant patients with PCOs: A double-blind randomized clinical trial. IJRM 2013; 11 (8) :611-0
URL: http://ijrm.ir/article-1-457-en.html
URL: http://ijrm.ir/article-1-457-en.html
Sedigheh Amooee * 
1, Mohammad Ebrahim Parsanezhad2 , Maryam Ravanbod Shirazi2 , Saeed Alborzi2 , Alamtaj Samsami2
1, Mohammad Ebrahim Parsanezhad2 , Maryam Ravanbod Shirazi2 , Saeed Alborzi2 , Alamtaj Samsami2
1- Department of Obstetrics and Gynecology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran , sedighehamooee@gmail.com
2- Department of Obstetrics and Gynecology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2- Department of Obstetrics and Gynecology, Shahid Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Abstract: (6759 Views)
Background: Chromium picolinate could be effective in clomiphen citrate resistant PCOS patients.
Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients.
Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200μg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well.
Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500).
Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates.
Objective: To compare the effects of chromium picolinate vs. metformin in clomiphen citrate resistant PCOS patients.
Materials and Methods: The present randomized clinical trial was performed on 92 women with clomiphen citrate-resistant PCOS at the clinics which were affiliated to Shiraz University of Medical Sciences, Shiraz, Iran. The subjects were randomly assigned to two groups receiving either chromium picolinate (200μg daily) or metformin (1500mg daily) for 3 months. Anthropometric and hormonal profile were measured and compared both before and after the treatment. Ovulation and pregnancy rate was measured in the two study groups, as well.
Results: Chromium picolinate significantly decreased fasting blood sugar (FBS) after 3 months of treatment (p=0.042). In the same way, the serum levels of fasting insulin had significantly decreased leading to an increase in insulin sensitivity as measured by QUICKI index (p=0.014). In comparison to the patients who received chromium picolinate, those who received metformin had significantly lower levels of testosterone (p=0.001) and free testosterone (p=0.001) after 3 months of treatment. Nevertheless, no significant difference was found between the two study groups regarding ovulation (p=0.417) and pregnancy rates (p=0.500).
Conclusion: Chromium picolinate decreased FBS and insulin levels and, thus, increased insulin sensitivity in clomiphene citrate-resistance PCOS women. These effects were comparable with metformin; however, metformin treatment was associated with decreased hyperandrogenism. Overall, chromium picolinate was better tolerated compared to metformin; nonetheless, the two study groups were not significantly different regarding ovulation and pregnancy rates.
Type of Study: Original Article |
References
1. Parsanezhad ME, Alborzi S, Zarei A, Dehbashi S, Omrani G. Insulin resistance in clomiphene responders and non-responders with polycystic ovarian disease and therapeutic effects of metformin. Int J Gynaecol Obstet 2001; 75: 43-50. [DOI:10.1016/S0020-7292(01)00470-2]
2. Whitaker KN. Polycystic ovary syndrome: an overview. J Pharm Pract 2011; 24: 94-101. [DOI:10.1177/0897190010384632]
3. Lucidi RS, Thyer AC, Easton AC, Holden AC, Schenken RS, Brzyski RG. Effect of chromium supplementation on insulin resistance and ovarian and menstrual cyclicity in women with polycystic ovary syndrome. Fertil Steril 2005; 84: 1755-1757. [DOI:10.1016/j.fertnstert.2005.06.028]
4. Badawy A, Elnashar A. Treatment options for polycystic ovary syndrome. Int J Womens Health 2011; 3: 25-35. [DOI:10.2147/IJWH.S11304]
5. Lydic ML, McNurlan M, Bembo S, Mitchell L, Komaroff E, Gelato M. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril 2006; 86: 243-246. [DOI:10.1016/j.fertnstert.2005.11.069]
6. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril 2004; 81: 19-25. [DOI:10.1016/j.fertnstert.2003.10.004]
7. Azziz R, Dewailly D, Owerbach D. Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78: 810-815.
8. White PC, Curnow KM, Pascoe L. Disorders of steroid 11β-hydroxylase isozymes. Endocr Rev 1994; 15: 421-438. [DOI:10.1210/edrv-15-4-421]
9. Stearns DM. Is chromium a trace essential metal? Biofactors 2000; 11: 149-162. [DOI:10.1002/biof.5520110301]
10. Hummel M, Standl E, Schnell O. Chromium in metabolic and cardiovascular disease. Horm Metab Res. 2007; 39: 743-51. [DOI:10.1055/s-2007-985847]
11. Wang ZQ, Cefalu WT. Current concepts about chromium supplementation intype2 diabetes and insulin resistance. Curr Diab Rep 2010; 10: 145-151. [DOI:10.1007/s11892-010-0097-3]
12. Kazerooni T, Dehghan-Kooshkghazi M. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome. Gynecol Endocrinol 2003; 17: 51-56. [DOI:10.1080/gye.17.1.51.56]
13. Genazzani AD, Battaglia C, Malavasi B, Strucchi C, Tortolani F, Gamba O. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004; 81: 114-119. [DOI:10.1016/j.fertnstert.2003.05.020]
14. Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynecol Obstet 2004; 87: 237-241. [DOI:10.1016/j.ijgo.2004.08.015]
15. Anderson RA. Effects of chromium on body composition and weight loss. Nutr Rev 1998; 56: 266-270. [DOI:10.1111/j.1753-4887.1998.tb01763.x]
16. Albarracin CA, Fuqua BC, Evans JL, Goldfine ID. Goldfine Chromium picolinate and biotin combination improves glucose metabolism in treated uncontrolled overweight to obese patients with type 2 diabetes. Diabetes Metab Res Rev 2008; 24: 41-51. [DOI:10.1002/dmrr.755]
17. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenisim and hyper insulinemia in women with polycystic ovary syndrome Fertil Steril 2000; 73: 1149-1154. [DOI:10.1016/S0015-0282(00)00501-X]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
